Advertisement

First Edition

March 12, 2019

  • Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Ian W. Flinn, John G. Gribben, Martin J.S. Dyer, William Wierda, Michael B. Maris, Richard R. Furman, Peter Hillmen, Kerry A. Rogers, Swaminathan Padmanabhan Iyer, Anne Quillet-Mary, Loic Ysebaert, Harriet S. Walter, Maria Verdugo, Christian Klein, Huang Huang, Yanwen Jiang, Gerard Lozanski, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher and Thomas J. Kipps

March 11, 2019

March 08, 2019

  • Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
    Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, Carla Casulo, Steven Le Gouill, Laurie H. Sehn, Herve Tilly, Guillaume Cartron, Martine E.D. Chamuleau, Andre Goy, Constantine S. Tam, Pieternella J. Lugtenburg, Adam M. Petrich, Arijit Sinha, Divya Samineni, Sylvia Herter, Ellen Ingalla, Edith Szafer-Glusman, Christian Klein, Deepak Sampath, Martin Kornacker, Mehrdad Mobasher and Franck Morschhauser

March 06, 2019

  • Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
    John C. Byrd, Peter Hillmen, Susan O'Brien, Jacqueline C. Barrientos, Nishitha M. Reddy, Steven Coutre, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Patrick Thornton, Carol Moreno, Marco Montillo, John M. Pagel, Jan A. Burger, Jennifer A. Woyach, Sandra Dai, Remus Vezan, Danelle F. James and Jennifer R. Brown

March 04, 2019

February 28, 2019

February 27, 2019

February 26, 2019

February 25, 2019

February 22, 2019

February 19, 2019

February 15, 2019

  • Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
    Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie L. Batlevi, Philip C. Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin Jr., Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette N. Owens, M. Lia Palomba, Anas Younes and David J. Straus

February 13, 2019

February 12, 2019

February 11, 2019

February 05, 2019

  • Human megakaryocytes possess intrinsic anti-viral immunity through regulated induction of IFITM3
    Robert A. Campbell, Hansjorg Schwertz, Eugenio D. Hottz, Jesse W. Rowley, Bhanu Kanth Manne, A. Valance Washington, Robert Hunter-Mellado, Neal D. Tolley, Miles Christensen, Alicia S. Eustes, Emilie Montenont, Seema Bhatlekar, Cassandra H. Ventrone, Beth D. Kirkpatrick, Kristen K. Pierce, Stephen S. Whitehead, Sean A. Diehl, Paul F. Bray, Guy A. Zimmerman, Yasuhiro Kosaka, Patricia T. Bozza, Fernando A. Bozza, Andrew S. Weyrich and Matthew T. Rondina
  • Dominant activating RAC2 mutation with lymphopenia, immunodeficiency and cytoskeletal defects
    Amy P. Hsu, Agnes Donkó, Megan E. Arrington, Muthulekha Swamydas, Danielle Fink, Arundhoti Das, Omar Escobedo, Vincent Bonagura, Paul Szabolcs, Harry N. Steinberg, Jenna Bergerson, Amanda Skoskiewicz, Melanie Makhija, Joie Davis, Ladan Foruraghi, Cindy Palmer, Ramsay L. Fuleihan, Joseph A. Church, Avinash Bhandoola, Michail S. Lionakis, Sharon Campbell, Thomas L. Leto, Douglas Kuhns and Steven M. Holland

January 30, 2019

January 28, 2019

January 17, 2019

January 07, 2019

November 28, 2018

November 14, 2018

December 06, 2017

December 04, 2017

July 24, 2012

October 20, 2010

  • MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma
    Moshe E. Gatt, Jian-Jun Zhao, Margaret S. Ebert, Yunyu Zhang, Zhangbo Chu, Mala Mani, Roi Gazit, Daniel E. Carrasco, Jui Dutta-Simmons, Sophia Adamia, Stéphane Minvielle, Yu-Tzu Tai, Nikhil C. Munshi, Hervé Avet-Loiseau, Kenneth C. Anderson and Daniel R. Carrasco

Pages